Name: Latest research reports of Abbott India Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Abbott India Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Abbott India Ltd.

NSE: ABBOTINDIA | BSE: 500488 | ISIN: INE358A01014 | Industry: Pharmaceuticals
| Expensive Performer

34290.0000 -130.00 (-0.38%)

NSE Jul 14, 2025 13:42 PM

35.40% Gain from 52W Low

Volume: 1,393

Abbott India Ltd.

29 Apr 2025

34290.00

-0.38%

ERRATA: Abbott India (BUY): Mixtard discard to result in highest-ever EBITDA margin

Buy: Abbott India Ltd.

BOB Capital Markets Ltd.

Novo Nordisk insulin brand outgo to result in 330 bps and 670 bps increase in EBITDA margin to 30.9% and 34.9% for FY26E and FY27E

Abbott India Ltd. has gained 20.08% in the last 6 Months